Highlights of BioNTech's oncology programs to be presented at AACR 2025: ...

QPS, a leading global contract research organization (CRO) specializing in preclinical and clinical drug development services ...

Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned for ...

Over the last decade there has been a move to reduce the amount of preclinical work requiring the use of sentient animals.

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

Bayer and Vividion Therapeutics to present latest research on their advancing oncology portfolio at AACR 2025 annual meeting: Berlin, Germany Wednesday, April 23, 2025, 10:00 Hrs ...

A rice-sized microrobot offers precision in brain surgery, starting with tumor biopsies in a first clinical trial set for ...

The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candi ...

Scale-up is a common problem encountered in all forms of development across industries, and oral solid dose manufacturing ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

"We are excited to see that the FDA is elevating its continued commitment to reduce animal testing through innovative science, as outlined in the new Roadmap to Reducing Animal Testing in Preclinical ...